Replies to post #232319 on Biotech Values

[DewDiligence]

ALT starting phase-2 trial of HepTcell for HBV:

https://www.globenewswire.com/news-release/2020/06/22/2051121/0/en/Altimmune-Announces-IND-Clearance-for-a-Phase-2-Trial-of-HepTcell-Immunotherapeutic-for-the-Treatment-of-Chronic-Hepatitis-B.html

HepTcell is an immunotherapeutic product candidate composed of nine synthetic HBV-derived peptides formulated with IC31, a TLR9-based adjuvant from Valneva SE. The HBV peptides were designed to drive T cell responses against all HBV genotypes in patients of diverse genetic background.

[DewDiligence]

ALT slides off the COVID-19 bandwagon:

https://www.globenewswire.com/news-release/2021/06/29/2255167/0/en/Altimmune-Announces-Update-on-AdCOVID-Phase-1-Clinical-Trial.html

Although antibodies were detected that bound the SARS-CoV-2 Spike protein and neutralized the virus in a subset of subjects, the magnitude of the response and the percent of subjects responding to AdCOVID were substantially lower than what had been demonstrated for other vaccines already authorized for emergency use. Based on these data, and in view of the highly competitive COVID-19 vaccine landscape, Altimmune is discontinuing further development of AdCOVID…